|
End-of-day quote
Korea S.E.
02/09/2026
|
5-day change | 1st Jan Change | ||
| 5,630.00 KRW | -4.41% |
|
+1.44% | -17.45% |
| 12-09 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/06/25 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Business description: GC Genome Corporation

Executive Committee: GC Genome Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Chang-Seok Gi
CEO | Chief Executive Officer | 57 | 25/03/2020 |
Sang-Hun Jeong
DFI | Director of Finance/CFO | 50 | 26/03/2025 |
Seu-Nga Hyun
AUD | Comptroller/Controller/Auditor | 45 | 28/03/2024 |
Eun-Hae Jo
PRN | Corporate Officer/Principal | 52 | - |
Composition of the Board of Directors: GC Genome Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Sang-Uk Kim
BRD | Director/Board Member | 57 | 29/03/2023 |
Company details: GC Genome Corporation

Medical & Diagnostic Laboratories
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -4.41% | +1.44% | -23.92% | - | 98.04M | ||
| +1.37% | -3.93% | +92.02% | +420.10% | 46.87B | ||
| +1.24% | -1.21% | +21.14% | +60.55% | 26.9B | ||
| +2.30% | -4.58% | -15.66% | -40.29% | 6.64B | ||
| +0.24% | -1.01% | +7.67% | +132.42% | 5.96B | ||
| +0.73% | -0.20% | +15.81% | +78.07% | 3.39B | ||
| +2.25% | -3.95% | -32.35% | +1,829.25% | 2.59B | ||
| -0.29% | +0.17% | +97.50% | +14.70% | 2.24B | ||
| +5.30% | +5.41% | +29.15% | +33.54% | 2.09B | ||
| -2.60% | -5.64% | -13.69% | -55.31% | 1.83B | ||
| Average | +0.64% | -1.44% | +17.77% | +274.78% | 9.86B | |
| Weighted average by Cap. | +1.31% | -3.45% | +51.17% | +272.46% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- A340450 Stock
- Company GC Genome Corporation
Select your edition
All financial news and data tailored to specific country editions

















